Clinical trial

Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease

NCT03283059

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Octohydroaminoacridine Succinate Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Aricept Normalized identity: AriceptView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebos Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2017-08-16

PhasePHASE3

Conditions

Alzheimer Diseaseverified · MONDO: Alzheimer disease

Interventions

Octohydroaminoacridine SuccinateDRUG

AriceptDRUG · verified · RxNorm: Aricept

PlacebosDRUG

Sponsors & collaborators

Shanghai Mental Health Centerlead sponsor

Changchun Huayang High-tech Co., Ltdcollaborator

Jiangsu Sheneryang High-tech Co., Ltdcollaborator

Mapped research locations

ShanghaiShanghai Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03283059 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.